Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
MTD of the combination of ixabepilone and temsirolimus, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)
Best response, defined to be the best objective status recorded from the start of the treatment until disease progression/recurrence
Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0